Publications by authors named "J P Geisler"
Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.
View Article and Find Full Text PDFActin polymerization counteracts prewetting of N-WASP on supported lipid bilayers.
Proc Natl Acad Sci U S A
December 2024
Article Synopsis
- Cortical condensates are transient structures that form in the actin cortex of oocytes and are rich in actin and N-WASP, forming through a phase separation process influenced by chemical kinetics.
- The study reveals that N-WASP can undergo surface condensation on lipid bilayers, which is a key factor in the formation of these condensates.
- The dynamics of condensate formation are regulated by a balance between their creation at the surface and the polymerization of actin, shedding light on the control of complex intracellular structures.
Article Synopsis
- Mitochondrial dysfunction is an early issue in ALS, and this study investigates the potential of 2,4-dinitrophenol (DNP), a mitochondrial uncoupler, as a treatment for ALS in a mouse model.
- Mice were given varying doses of DNP from early stages of the disease, and their motor skills and muscle function were assessed regularly, showing improvements in coordination, muscle performance, and reduced inflammation.
- The findings suggest that DNP can delay disease onset and even lead to recovery in motor abilities for symptomatic mice, indicating its potential as a novel treatment option for ALS if properly timed and dosed.
Introduction: This report presents a case of an exceptionally delayed distant recurrence of a choroidal melanoma, occurring 4 decades after the enucleation of the affected eye.
Case Presentation: In 1977, a 29-year-old man underwent enucleation for a choroidal melanoma. At the age of 68 years, he was diagnosed with advanced prostate cancer.
Article Synopsis
- Older patients with advanced hormone receptor-positive/HER2-negative breast cancer benefit from combining CDK4/6 inhibitors with standard endocrine therapy, according to recent studies.
- There is a higher risk of side effects from these inhibitors in older patients, leading to a trend of starting them on lower doses, although this practice lacks strong evidence.
- The IMPORTANT-trial aims